Theravance Biopharma, Inc. (NASDAQ:TBPH) Short Interest Update

Theravance Biopharma, Inc. (NASDAQ:TBPH) was the recipient of a significant drop in short interest in the month of August. As of August 14th, there was short interest totaling 1,714,947 shares, a drop of 58.9% from the July 30th total of 4,168,511 shares. Approximately 3.6% of the shares of the stock are short sold. Based on an average daily volume of 683,553 shares, the short-interest ratio is presently 2.5 days.

Theravance Biopharma Price Performance

TBPH stock traded up $0.01 during trading on Friday, reaching $17.05. 414,568 shares of the company were exchanged, compared to its average volume of 522,291. The company has a market capitalization of $885.22 million, a price-to-earnings ratio of 16.88 and a beta of 0.19. The company has a 50-day moving average of $16.96 and a two-hundred day moving average of $16.63. Theravance Biopharma has a twelve month low of $13.08 and a twelve month high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.18). Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. The company had revenue of $20.73 million during the quarter, compared to analyst estimates of $22.49 million. On average, analysts forecast that Theravance Biopharma will post 1.56 EPS for the current year.

Wall Street Analyst Weigh In

TBPH has been the subject of several recent research reports. BTIG Research cut shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 29th. Wall Street Zen cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings upgraded Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, August 17th. Zacks Research raised Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. Finally, JonesTrading downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, Theravance Biopharma currently has an average rating of “Hold” and a consensus target price of $19.40.

Insider Activity at Theravance Biopharma

In other news, major shareholder Eli Samaha sold 273,871 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $17.23, for a total value of $4,718,797.33. Following the transaction, the insider directly owned 9,237,279 shares of the company’s stock, valued at $159,158,317.17. The trade was a 2.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Rhonda Farnum sold 13,314 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $16.39, for a total value of $218,216.46. Following the completion of the transaction, the senior vice president directly owned 232,457 shares in the company, valued at approximately $3,809,970.23. This represents a 5.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 350,011 shares of company stock valued at $6,008,309 in the last 90 days. 7.65% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Theravance Biopharma

Several large investors have recently modified their holdings of the business. Quarry LP acquired a new stake in Theravance Biopharma in the third quarter valued at $26,000. Caitong International Asset Management Co. Ltd grew its position in shares of Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 1,411 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 781 shares during the last quarter. CIBC Private Wealth Group LLC increased its stake in shares of Theravance Biopharma by 20,269.6% in the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 4,662 shares during the period. Finally, AQR Capital Management LLC bought a new position in shares of Theravance Biopharma during the first quarter worth about $101,000. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.